Faeth Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Faeth Therapeutics, Inc. (FTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $21.04 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-04
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $7.02, a 1797.30% increase year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $0.37.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $1.10.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $7.17, a 26.69% decline from fiscal 2024.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $9.78, a 887.88% increase from fiscal 2023.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $0.99, a 59.92% decline from fiscal 2022.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.47, a 79.62% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $21.04 10-Q · filed 2026-08-04 | ||||
| 2026-03-31 | $7.02 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | $7.17 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $7.17 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | $7.17 10-Q · filed 2025-08-05 | ||||
| 2025-03-31 | $0.37 10-Q · filed 2025-05-06 | ||||
| 2024-12-31 | $9.78 10-K · filed 2026-03-30 | $0.49 10-K · filed 2025-03-28 | |||
| 2024-09-30 | $0.58 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $0.58 10-Q · filed 2024-08-06 | ||||
| 2023-12-31 | $0.99 10-K · filed 2025-03-28 | ||||
| 2023-09-30 | $1.05 10-Q · filed 2023-11-07 | ||||
| 2023-06-30 | $1.10 10-Q · filed 2023-08-03 | ||||
| 2023-03-31 | $1.10 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $2.47 10-K · filed 2024-02-29 | ||||
| 2022-09-30 | $2.50 10-Q · filed 2022-11-08 | ||||
| 2021-12-31 | $12.12 10-K · filed 2023-03-29 | ||||
| 2020-12-31 | $3.09 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |